SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Microcap & Penny Stocks : Pharmos(PARS) -- Ignore unavailable to you. Want to Upgrade?


To: crysball who wrote (1208)9/2/1998 12:59:00 PM
From: Ariella  Read Replies (1) | Respond to of 1491
 
Dear Crysball, Tamoxifen in the news

Are you sure it's approved or just under review?

biz.yahoo.com

PARS has finished preclinical work on its tamoxifen analog and is debating whether to do an additional toxicity test. I hope we do since efficacy AND safety are part of our core business plan.

ENMD, PARS, GNE, XEN.L <-- the emerging competitors....

-Ariella